Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 15;13:898955. doi: 10.3389/fphar.2022.898955

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Hong, Lu, Wu, Chen, Chen, Zhang, Huang and Cui.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effects and mechanisms of paeoniflorin in Parkinson’s disease. Paeoniflorin administration may ameliorate MPTP-induced impairment of spontaneous motor performance and inhibit MPTP-induced loss of dopaminergic neuron loss by increasing the expression of dopaminergic transporters and tyrosine hydroxylases, decreasing MAO-B and caspase-3/9 activity, or increasing Akt activity via a possible mechanism related to adenosine A1 receptor activation. Under in vitro conditions, paeoniflorin was found to suppress MPP⁺ or acidosis-induced accumulation of α-synuclein in cultured PC12 cells by inhibiting the activity or expression of ASICs. However, whether this in vitro effect on ASICs could mediate the neuroprotective effect of paeoniflorin in animal models of Parkinson’s disease remains unclear.